Yu Dianke, Shi Juan, Sun Tong, Du Xiaoli, Liu Li, Zhang Xiaojiao, Lu Chao, Tang Xiaohu, Li Meng, Xiao Lingchen, Zhang Zhouwei, Yuan Qipeng, Yang Ming
State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Tumour Biol. 2012 Jun;33(3):877-84. doi: 10.1007/s13277-011-0314-y. Epub 2012 Jan 17.
The excision repair cross-complementation group 1 (ERCC1) plays an essential role in DNA repair and has been linked to resistance to platinum-based anticancer drugs among advanced non-small cell lung cancer (NSCLC) patients. We systematically evaluate whether ERCC1 Asn118Asn and C8092A genetic variants are associated with treatment response of platinum chemotherapy. We preformed a meta-analysis using ten eligible cohort studies (including 11 datasets) with a total of 1,252 NSCLC patients to summarize the existing data on the association between the ERCC1 Asn118Asn and C8092A polymorphisms and response to platinum regiments. Odds ratio or hazard ratio with 95% confidence interval were calculated to estimate the correlation. We found that neither ERCC1 C8092A polymorphism nor Asn118Asn variant is associated with different response of platinum-based treatment among advanced NSCLC patients. Additionally, these two genetic variants are not related to treatment response in either Caucasian patients or Asian patients. Our meta-analysis indicates that the ERCC1 Asn118Asn and C8092A polymorphisms may not be good prognostic biomarkers for platinum-based chemotherapy in patients with stage III-IV NSCLC.
切除修复交叉互补组1（ERCC1）在DNA修复中起重要作用，并且与晚期非小细胞肺癌（NSCLC）患者对铂类抗癌药物的耐药性有关。我们系统地评估ERCC1 Asn118Asn和C8092A基因变异是否与铂类化疗的治疗反应相关。我们使用十项符合条件的队列研究（包括11个数据集）进行了一项荟萃分析，这些研究共有1252例NSCLC患者，以总结关于ERCC1 Asn118Asn和C8092A多态性与铂类方案反应之间关联的现有数据。计算比值比或风险比及95%置信区间以估计相关性。我们发现，ERCC1 C8092A多态性和Asn118Asn变异均与晚期NSCLC患者对铂类治疗的不同反应无关。此外，这两种基因变异在白种人患者或亚洲患者中均与治疗反应无关。我们的荟萃分析表明，ERCC1 Asn118Asn和C8092A多态性可能不是III-IV期NSCLC患者铂类化疗的良好预后生物标志物。
